Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions
Journal of Clinical Oncology2007Vol. 25(17), pp. 2420–2425
Citations Over TimeTop 1% of 2007 papers
Anthony V. D’Amico, James W. Denham, Juanita Crook, Ming‐Hui Chen, Samuel Z. Goldhaber, David S. Lamb, David Joseph, Keen‐Hun Tai, Shawn Malone, Charles Ludgate, Allison Steigler, Philip W. Kantoff
Abstract
The use of AST is associated with earlier onset of fatal MIs in men age 65 years or older who are treated for 6 months compared with men who are not treated with AST.
Related Papers
- → How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk(2021)42 cited
- → Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer(2011)9 cited
- → Androgen deprivation therapy for prostate cancer(2017)4 cited
- Complications of androgen deprivation therapy in prostate cancer / a review(2017)
- → PCN151 Major Adverse Cardiovascular Event Hospitalization Burden in Patients with Prostate Cancer (PC) Receiving Androgen Deprivation Therapy (ADT) in the United States(2020)